【24h】

Identification of candidate drugs for the treatment of ALS

机译:确定用于治疗ALS的候选药物

获取原文
获取原文并翻译 | 示例
           

摘要

A consortium of investigators interested in neurodegenerative diseases collaborated to screen 1040 drugs in multiple neurodegenerative disease assays. One model of amyotrophic lateral sclerosis (ALS) pathogenesis in particular incorporated glutamate exposure in enriched primary rat motor neuron cultures. In this model 78 compounds decreased motor neuron death caused by 100 mu M glutamate. Almost all these pharmacological agents act at one or more of the following cellular targets: 1) protein synthesis inhibition; 2) Cox inhibition; 3) regulation of anion flux; 4) modulation of GABA receptors; 5) antioxidant, and 6) cell cycle inhibition. The most prevalent mode of action was the regulation of intracellular calcium. These data extend the understanding of motor neuron degeneration and identify a number of cellular targets for the improvement of combined therapies for neurodegenerative disease.
机译:一个对神经退行性疾病感兴趣的研究者联盟在多种神经退行性疾病分析中合作筛选了1040种药物。肌萎缩性侧索硬化症(ALS)发病机理的一种模型特别是将谷氨酸暴露纳入了丰富的原代大鼠运动神经元培养物中。在该模型中,有78种化合物减少了100μM谷氨酸引起的运动神经元死亡。几乎所有这些药理作用于以下一种或多种细胞靶标:1)抑制蛋白质合成; 2)抑制COX; 3)调节阴离子通量; 4)调节GABA受体; 5)抗氧化剂,和6)细胞周期抑制。最普遍的作用方式是调节细胞内钙。这些数据扩展了对运动神经元变性的理解,并确定了许多用于改善神经退行性疾病综合疗法的细胞靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号